Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Autologous and allogeneic hematopoietic stem cell transplantation represent potentially curative options for some patients, while the field of non-transplant cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapies, CAR natural killer cell therapies, and genetically modified T-cell receptors, is also expanding to offer more patients curative options.
Advertisement
Advertisement
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Azercabtagene zapreleucel applies a novel approach of combining lymphodepletion chemotherapy with interleukin-2.
The FDA approvals of CAR T-cell therapies have changed the treatment landscape for several hematologic malignancies.
The experts focused on cilta-cel when comparing the three FDA-approved treatments' efficacies, toxicities, and availability.
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Cema-cel is feasible and can induce durable responses in patients with LBCL, achieving an ORR of 58% and a CR rate of 42%.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
Real-world data shows evolving treatment strategies and clinical decision-making.
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
Adding ruxolitinib before, during, and after HSCT to standard GVHD prophylaxis reduced the incidence of GVHD.
Scientific evidence indicates that CAR-T can be safely administered on an outpatient basis at specialized medical centers.
Findings from a subgroup analysis of ZUMA-7 support early referral to axi-cel therapy.
In a prospective study patients with Fanconi anemia were matched to healthy controls and underwent carotid artery ultrasound.
Patient-reported response is associated with overall response, total symptom score response, and failure-free survival.
In the TRANSCEND FL trial liso-cel has met primary and secondary endpoints for both MZL and FL with manageable safety.
The positive opinion is based on results from the phase II TRANSCEND FL study, in which liso-cel showed an ORR of 97.1%.
This new indication for the injection alkylating agent pertains to adult or pediatric patients aged one year and older.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
The CRL is related to observations of a third-party manufacturing facility as part of a standard prelicense inspection.
The first-of-its-type anti-CSF-1R antibody is approved for use in adult and pediatric patients who weigh at least 40 kg.
Patient-reported outcomes of the CARTITUDE-4 trial showed an improvement in quality of life with cilta-cel versus SOC.
CAR-T achieves favorable responses and survival in relapsed or refractory LBCL in both the second- and third-line setting.
The therapy under evaluation by two ongoing studies involves a new accelerated CAR T-cell product manufacturing process.
The 5-year follow-up analysis of ZUMA-5 showed continued efficacy and no new safety signals.
The phase 1b study of CAR22 is ongoing, and investigators are currently looking to enroll more patients.
Dr. Matthew Cortese reported that CAR T-cell therapy appears to overcome some of the adverse prognostic impact.
The study used a standard 3+3 dose escalation design to evaluate the results of SYNCAR-001 plus STK-009.
Data support rituximab over watchful waiting in front-line therapy for low-tumor-burden follicular lymphoma, study concludes.
A compound to assist CAR T-cell therapy by targeting and suppressing YTHDF2 is in development.
A new investigator-initiated trial in China will investigate KJ-C2219 for relapsed or refractory B-cell non-Hodgkin lymphoma.
Approval was granted by the FDA on the basis of findings from the phase 3 MSB-GVHD001 clinical trial.
Limitations on benefits from immunotherapy in this setting increase clinical interest in this CAR T-cell therapy approach.
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
Encouraging initial study findings in mice will inform the design of a BHB supplementation trial in human patients.
A large, multicenter retrospective study found favorable efficacy and toxicity with this approach.
Odronextamab monotherapy showed promising efficacy in patients with high-risk, grade 1-3a follicular lymphoma.
Robust responses with favorable safety has been demonstrated with tisagenlecleucel in relapsed or refractory Fl.
Favorable preclinical outcomes were demonstrated with VX765 treatment.
Upfront treatment with fixed-duration subcutaneous mosunetuzumab demonstrated a high complete response rate in FL and MZL.
Phase 1 study results hint response durability for novel CAR-T agent, CAR22 in certain patients with large B-cell lymphoma.
Molecular features typically associated with inferior outcomes did not significantly affect survival or CAR-T response.
Liso-cel plus ibrutinib demonstrates substantial efficacy, deep remissions, and manageable safety.
Although liso-cel has a higher total cost than mosunetuzumab, it provides increased survival and reduced time toxicity.
Patients treated with tisa-cel, axi-cel, or liso-cel had an ORR of 65% and a one-month CR rate of 46%.
A study has compared responses with anti-CD19 CAR-T therapy in MCL with and without active CNS involvement at infusion.
An MAIC analysis of data from clinical trials identified differences in efficacy and safety between the two interventions.
The authors found the complete response rate results to be promising and to warrant further clinical investigation.
Bilal Abid, MD, describes how to approach sequencing pirtobrutinib after CAR-T therapy.
Dr. Abid describes when he uses bispecifics versus CAR-T in his practice at the University of Texas Health Science Center.
Encouraging efficacy and safety seen over 17 months in a phase II trial continued into the trial's 29-month follow-up period.
In a retrospective study bendamustine compared favorably with the cyclophosphamide plus fludarabine lymphodepletion regimen.
A first ever phase I/II trial tested escalating doses in patients with relapsed or refractory disease.
Axi-cel produced sustained long-term responses in patients with follicular lymphoma and marginal zone lymphoma.
A phase II trial found antitumor effect across patient subgroups and independently of risk factors for disease progression.
Treatment with liso-cel was effective and safe in patients with relapsed or refractory follicular lymphoma in TRANSCEND FL.
Manali Kamdar, MD, shared results from the pivotal phase III TRANSFORM study on lisocabtagene maraleucel in LBCL.
Patients with relapsed refractory LBCL can derive clinical benefit from liso-cel NCP without compromising safety.
The median progression-free survival, duration of response, and overall survival were not reached.
Benefits of CAR T-cell therapy outweigh the hypothetical future risk of secondary malignancies.
In approximately 12,000 reports of adverse events, the researchers found 19 cases of T-cell malignancies after CAR-T.
The investigators reviewed case reports of patients 20 years old and younger who underwent therapy for BPDCN.
HMA plus venetoclax was found to be effective and well tolerated in patients with AML who relapsed after HSCT.
Adding ofatumumab to reduced intensity conditioning is safe and effective in high-risk B-cell non-Hodgkin lymphoma.
The study also explored the role of this combination in transitioning patients to HSCT.
The award grants $100,000 to a postdoctoral or early-career oncology researcher from a racial/ethnic minority group.
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
Approach-oriented coping was associated with higher quality of life and lower symptoms of depression and anxiety.
The study used public data from various online sources related to approved CAR-T therapies for MM.
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days.
ZUMA-7 showed that axi-cel significantly improved OS compared with standard of care in relapsed or refractory LBCL.
The latest HemOnc Pulse episode looks at the science behind the statement from the FDA on the risk of CAR-T therapies.
Patients' coping strategies prior to HSCT had significant effects on their psychological distress and quality of life.
Shernan Holtan, MD, and the hosts discuss recent data on graft versus host disease prophylaxis.
GVHD affects approximately 30,000 Americans, according to Dr. Michael Chancellor, Chief Medical Officer at Lipella.
The investigation is "likely not going to change the risk-benefit profile of these approved products," Dr. Chari said.
Dr. Osman discussed menin inhibitors for leukemia, and axatilimab treatment for graft-versus-host disease.
The analysis included 346 patients with CALR-mutated MF who were transplanted in 123 centers between 2005 and 2019.
Here’s what they add to the treatment toolbox for hematologic malignancies.
In this episode of "The Fellow on Call," the hosts focus on CAR-T, bispecific antibodies, and more.
Dr. de Lima discusses progress and remaining challenges with allogeneic CAR-T and other cellular therapy products.
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Critical drugs used to treat cancer are in short supply in the United States and around the globe.
Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches."
CART-ddBCMA is an investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma.
There was a median of two production slots per month from March 2021 to October 2021. All slots were filled.
The difference in infection rates between the treatment and placebo groups was not statistically significant.
Dr. DiPersio discusses events that shaped his career, his lab’s most transformative research, and the future of transplant.
Omidubicel-onlv is a “substantially modified” allogeneic cord blood-based cell therapy.
Dr. June has made “seminal contributions” to CAR T-cell therapy for blood cancers,
Nearly half of caregivers reported a high use of approach-oriented coping strategies.
None of the patients with DDX41 variants who received post-HSCT cyclophosphamide developed severe acute GVHD.
The overall neutrophil response rate, defined as recovery or improvement, was 84% within a median of nine days.
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
The study used natural language processing for computer-assisted review of electronic health records.
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
The research has implications for patients with hematologic malignancies who need to undergo allogeneic HSCT.
BMS-986393, a GPRC5D-directed CAR-T, had a "favorable” safety profile with “promising” preliminary efficacy in R/R MM.
Survival outcomes are typically poor in patients with relapsed/refractory aggressive BCL who relapse after anti-CD19 CAR-T.
Post-transplant cyclophosphamide]-based GVHD prophylaxis mitigates the development of gastrointestinal GVHD.
Children with R/R B-cell ALL who received co-administered CD19-and CD22-directed CAR-T therapy had a 99% CR.
Allogeneic CAR T-cells had “encouraging safety and efficacy” in patients with CD7-positive hematologic malignancies.
Axicabtagene ciloleucel led to higher response rates and higher toxicity rates than tisagenlecleucel in R/R DLBCL.
Allogeneic off-the-shelf CAR T-cells “showed evidence of antileukemic activity” in heavily pretreated patients...
Certain genetic features in tumor and plasma samples from patients with LBCL are associated with poor CD19-directed CAR-T...
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
CD19-directed CAR T-cells led to a complete remission in around half of patients with relapsed/refractory CNS lymphoma.
Health-related quality of life improved in patients with R/R MM following treatment with the CAR T-cell treatment...
Researchers have recently identified bacterial proliferation on the skin as a factor associated with the development of...
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Dr. Lentzsch and Dr. Wong discuss the role of transplantation in newly diagnosed systemic light chain (AL) amyloidosis...
Autologous chimeric antigen receptor (CAR) T-cell therapies have shown “unprecedented efficacy” in patients with ...
Carlos de Lima, MD, stopped by the Blood Cancers Today booth at the 2022 SOHO Annual Meeting to give his advice...
A conditioning regimen of clofarabine plus total body irradiation led to a two-year overall survival rate of 43%
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Researchers had not previously studied the long-term impact of omidubicel...
New research suggests venetoclax-containing regimens with intensive treatment and may improve outcomes.
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
The combination led to an overall survival rate of nearly 75% in patients with BPDCN...
First-line treatment with tagraxofusp led to an overall response rate of 75% in patients with blastic plasmacytoid...
Blood Cancers Today spoke with clinicians about the two available second-line chimeric antigen receptor T-cell therapies...
A second allogeneic HSCT is a reasonable treatment option for patients with relapsed AML.
The largest study yet comparing chimeric antigen receptor (CAR) T-cell therapy with the previous standard of care (SOC)...
In second-line therapy for relapsed/refractory LBCL, which patients would you consider eligible for CAR T-cell therapy...
The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies.
Advances have been accomplished in the management of adults with acute lymphoblastic leukemia...
The CAR T-cell therapy received accelerated approval for adults with R/R FL after two or more lines of systemic therapy.
This article discusses managing the most difficult cases of CLL.
The analysis results have clinical implications, as venetoclax-based regimens are the standard of care for patients.
Researchers have demonstrated the clinical importance of COVID-19 vaccination after anti-CD19 chimeric antigen receptor (CAR) ...
Transplant was associated with a lower incidence of disease relapse but did increase the mortality related to treatment.
Nearly a third of patients with chronic graft-versus-host disease (GVHD) were able to discontinue long-term systemic therapy ...
The FDA has granted Fast Track Designation and Rare Pediatric Disease Designation for WU-CART-007.
Patients with newly diagnosed primary central nervous system lymphoma who received high-dose chemotherapy and autologous ...
Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell treatment, improved quality of life compared to standard of care ...
The phase Ib clinical trial is being launched by Cellenkos in partnership with Incyte as part of their LIMBER initiative.
Axicabtagene ciloleucel is the most cost-effective chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed ...
Results from the global, phase III TRANSFORM study support liso-cel as a new second-line treatment recommendation in patients ...
In patients with newly diagnosed MM, the addition of AHSCT to a triplet regimen of lenalidomide, bortezomib, and ...
The overall efficacy of tisagenlecleucel was similar between the two groups. Flu/Cy led to more profound lymphocytopenia ...
This article discusses optimizing transplant-related care for patients with high-risk acute lymphoblastic...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use recommended the conditional approval ...
Clinicians who specialize in BPDCN discuss the disease and novel therapeutic approaches to treating patients with BPCDN.
There was a global increase of 6.2% in autologous HSCT and 7.0% in allogeneic HSCT.
Researchers retrospectively analyzed 580 patients with AML receiving HSCT between January 1999 and November 2020.
Median PFS and OS were 25.8 months (95% CI, 9.6-47.6) and 46.6 months (95% CI, 24.9-not estimable), respectively.
Autologous hematopoietic stem cell transplantation improved survival outcomes for certain patients younger than 65.
CAR T-cell dysfunction marked by TIGIT expression may be driving poor response to therapy in patients with non-Hodgkin ...
Few patients with myeloma benefit from CAR-T cell therapy, according to a Viewpoint.
Black and Hispanic patients who underwent CAR T-cell therapy had outcomes comparable to their White and Asian counterparts.
A study of seven clinical trials around CAR T-cell therapies showed a substantially low enrollment of participants who were ...
University of Pennsylvania researchers have shortened the cell manufacturing process for CAR T-cell therapy, which is ...
Clinicians are excited to see how many patients could benefit with CAR T-cell therapy.
Allogene Therapeutics has been cleared by the U.S. Food and Drug Administration (FDA) to resume trials of its allogeneic ...
Director of the U.S. Food and Drug Administration’s (FDA’s) Oncology Center of Excellence Richard Pazdur, MD, has ...
On Feb. 15, Robert Califf, MD, was confirmed to lead the FDA as commissioner for the second time.
While the field of telehealth grew rapidly in the United States during the COVID-19 pandemic, many patients lack access to ...
In January, a private equity firm announced that it would buy MarketScan, a group of databases containing sensitive patient ...
The Government Accountability Office says the US Department of Health and Human Services is at high risk of mismanaging a ...
The FDA has approved an update to the prescribing information for all approved indications of axi-cel.
On average, pharmaceutical companies raised US list prices on cancer, diabetes, and other prescription drugs by 6.6% in the ...
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Abatacept has been U.S. Food and Drug Administraion (FDA)-approved as acute graft-versus-host disease (aGVHD) prophylaxis for ...
A study has characterized HLH–like manifestations as a CRS variant in certain young patients with leukemia/lymphoma.
Life expectancy has improved since 1974 but remains 20.8% lower compared with the general population.
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) significantly improved event-free ...
According to data from the ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) ...
In total, 668 patients were evaluated, including 126 Black patients and 542 white patients.
A study found that for people with MCL, patient demographics were associated with likelihood of receiving ASHCT.
This study was published in JCO Oncology Practice.
Return to work is a marker of functional recovery in patients with cancer.
Experts focus on the latest news and clinical development and impact for multiple myeloma.
The use of hematopoietic stem cell transplantation (AHCT) is associated with excellent 2-year outcomes in multiple myeloma ...
A study found no discernible difference in the usage rate of hematopoietic cell transplantation (HCT) between Black and White ...
Patient race and ethnicity were bound to be associated with hematopoietic stem/progenitor cells mobilization.
Janssen and Legend Biotech announced new data for BCMA-directed CAR-T cell therapy cilta-cel for relapsed/refactory MM.
Most guidelines recommend induction therapy followed by autologous HCT.
Clinical guidelines recommend upfront AHCT for eligible patients with MM.
Researchers from The Mount Sinai Health System in New York City evaluated racial disparities in time to autologous ...
Infection is a major driver of intensive care unit (ICU) admissions after hematopoietic cell transplantation (HCT), according ...
Nikhil Munshi, MD, had a conversation with Orsi Giricz, PhD, from LLS, to discuss the recent approval of Abecma and his role ...
The U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (ide-cel) for the treatment of adults with ...
A study published in Clinical Lymphoma, Myeloma & Leukemia evaluated the burden of outpatient autologous hematopoietic ...
Parameswaran Hari, MD, weighs in on clinical considerations for selecting CAR T cell therapy for multiple myeloma.
The latest updates from the KarMMA trial, published in The New England Journal of Medicine, showed that treatment with ...
Patients with multiple myeloma who underwent double autologous hematopoietic cell transplantation did not have better overall ...
An analysis of patients with multiple myeloma (MM) who underwent autologous hematopoietic cell transplant (AHCT) showed that ...
CT053 is a second-generation CAR T that incorporates a fully human BCMA-specific single-chain fragment variant.
Results from the PRIME study found that P-BCMA-101, an autologous CAR T-cell therapy, was effective and safe for patients ...
Nina Shah, MD, talks about two multiple myeloma agents granted priority review by the FDA and data on these therapeutics.
A study published in the Journal of Clinical Oncology found that ixazomib maintenance therapy extended survival in patients ...
Ankit Kansagra, MD, discusses chimeric antigen receptor T-cell agents in the pipeline for multiple myeloma.
Patients with CMML who received an allogeneic HSCT earlier in the course of their disease had better outcomes.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.